HIGHLIGHTS
SUMMARY
The use of autologous stem_cell transplantation (ASCT) following high-dose chemotherapy is a pillar of treatment of patients with various hematological malignancies. In candidates for ASCT, apheresis procedures should secure a minimum cell dose of 2 × 106 CD34+ cells/kg. When used as up-front mobilization, the combination of G-CSF and plerixafor significantly expands the proportion of MM and lymphoma patients achieving a satisfactory cell dose collection. To the up-front administration, plerixafor is used in many patients in the course of chemotherapy mobilization, based on a scarce CD34+ cell concentration before apheresis . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.